Home>>Signaling Pathways>> Cardiovascular>> Myocardial Contractility>>Neuropeptide Y (3-36) (human, rat) (trifluoroacetate salt)

Neuropeptide Y (3-36) (human, rat) (trifluoroacetate salt) (Synonyms: NPY (3-36) (human, rat))

Catalog No.GC44384

Neuropeptide Y (NPY) (3-36) is a C-terminal fragment of NPY, a neuropeptide involved in controlling appetite, blood pressure, cardiac contractility, and intestinal secretion.

Products are for research use only. Not for human use. We do not sell to patients.

Neuropeptide Y (3-36) (human, rat) (trifluoroacetate salt) Chemical Structure

Size Price Stock Qty
500μg
$170.00
In stock
1mg
$321.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Neuropeptide Y (NPY) (3-36) is a C-terminal fragment of NPY, a neuropeptide involved in controlling appetite, blood pressure, cardiac contractility, and intestinal secretion. NPY (3-36) is an endogenous peptide produced by cleavage of NPY by dipeptidyl peptidase 4 (DPP-4). It binds selectively to the NPY receptor Y2 (Ki = 0.41 nM in CHP 234 cells) over the Y1 receptor, where it does not bind at concentrations up to 1 µM. NPY (3-36) (0.1 nM) increases migration of human umbilical vein endothelial cells (HUVECs) by 80% after 12 hours in an in vitro wound closure assay. NPY (3-36) corresponds to residues 3-36 of the human and rat protein sequence.

Reviews

Review for Neuropeptide Y (3-36) (human, rat) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Neuropeptide Y (3-36) (human, rat) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.